COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy

• Status: Completed
• Trial end date: 2020-07-30
• Target enrollment: 0
• Participant gender: All

Summary

According to the epidemiological situation worldwide and the number of vaccinations made, there is little success in the fight against COVID-19. For many reasons, methylene blue is a promising drug for an active treatment against SARS-CoV-2 infected patients. Since methylene blue can work as a photosensitizer, photodynamic therapy as an antiviral treatment has great potential in the treatment of COVID-19. This clinical study investigated the effectiveness of SARS-CoV-2 infected people treatment using methylene blue and the following photodynamic therapy on the base of the L.L. Levshin Institute of Cluster Oncology (Department of Infectious Diseases №13) of I.M. Sechenov First Moscow State Medical University.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: I.M. Sechenov First Moscow State Medical University
• Collaborator: Prokhorov General Physics Institute of the Russian Academy of Sciences (GPI RAS)
• Treatments: Methylene Blue

Criteria

Inclusion Criteria:

• signed informed consent

• age: 18-90 years

• positive quantitative Polymerase Chain Reaction test on SARS-CoV-2 infection

• negative pregnancy test in women

• any severity of pneumonia (computer tomography scans)

Non-inclusion Criteria:

• documented refusal to participate in the study

• treatment with a serotonergic drug

• connection to artificial lung ventilation with or without sedation

• history of G-6-Phosphatase deficiency

• pregnancy and breastfeeding

• medical records of cirrhosis

• active chronic hepatitis

Exclusion Criteria:

• myocardial infarction, developed after the patient was included in the study, but before the intervention

• bleeding, developed after the patient was included in the study, but before the intervention

• connection to artificial lung ventilation developed after the patient was included in the study, but before the intervention